v3.24.3
Significant Events in the Reporting Period - Additional Information (Detail)
€ in Thousands
1 Months Ended
Sep. 23, 2024
EUR (€)
shares
Sep. 23, 2024
USD ($)
shares
Sep. 20, 2024
shares
Sep. 19, 2024
USD ($)
shares
Sep. 03, 2024
USD ($)
Multiple
Jan. 29, 2024
USD ($)
Sep. 30, 2024
EUR (€)
Multiple
Sep. 30, 2024
USD ($)
Multiple
Jan. 31, 2024
USD ($)
Sep. 30, 2024
kr / shares
Sep. 19, 2024
kr / shares
Dec. 31, 2023
EUR (€)
Sep. 30, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Significant Events In The Reporting Period LineItems                            
Nominal value per share | kr / shares                   kr 1        
Net proceeds from offering cost € 290,600 $ 323,600,000                        
Balance of equity | €             € 97,320         € 145,697 € 73,433 € (263,348)
American depository shares [member]                            
Significant Events In The Reporting Period LineItems                            
Nominal value per share | kr / shares                     kr 1      
Aggregate sale and issuance of share | shares 2,300,000 2,300,000                        
Exercised option to purchase | shares     300,000                      
Public offering price | shares       300,000                    
Sold at public offering price       $ 150                    
Issue of ordinary share | shares       2,000,000                    
Purchase by underwriters price       $ 141                    
Third Party Investors [Member]                            
Significant Events In The Reporting Period LineItems                            
Commitment from investors           $ 150,000,000     $ 150,000,000          
Ownership percentage                 42.00%          
Royalty Pharma [member]                            
Significant Events In The Reporting Period LineItems                            
Funding received in exchange of royalty payments               $ 150,000,000            
Royalty payment ending period             Dec. 31, 2029 Dec. 31, 2029            
Net proceeds from royalty funding agreement             € 134,200 $ 148,200,000            
Royalty Pharma [member] | Bottom of range [member]                            
Significant Events In The Reporting Period LineItems                            
Multiple of the purchase price were royalty payment will cease | Multiple             1.65 1.65            
Royalty Pharma [member] | Top of range [member]                            
Significant Events In The Reporting Period LineItems                            
Multiple of the purchase price were royalty payment will cease | Multiple             2 2            
Royalty Pharma U.S. Yorvipath [member]                            
Significant Events In The Reporting Period LineItems                            
Funding received in exchange of royalty payments               $ 150,000,000            
Funding received         $ 150,000,000     $ 150,000,000            
Net revenue from sales interest payment in percentage in exchange for funding         3.00%   3.00% 3.00%            
Royalty payment ending period         Dec. 31, 2029                  
Royalty Pharma U.S. Yorvipath [member] | Bottom of range [member]                            
Significant Events In The Reporting Period LineItems                            
Multiple of the purchase price were royalty payment will cease | Multiple         1.65                  
Royalty Pharma U.S. Yorvipath [member] | Top of range [member]                            
Significant Events In The Reporting Period LineItems                            
Multiple of the purchase price were royalty payment will cease | Multiple         2